jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

STD Profile

Reproductive

10 parameters

image

Report in 36Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Multipanel STD test (HIV, syphilis, gonorrhea, etc.).

₹3,999₹5,499

27% OFF

Parameters

  • List of Tests
    • HBsAG
    • Anti Chlamydia trachomatis Antibody IgG
    • Anti Chlamydia trachomatis Antibody IgM
    • Anti Hepatitis C Virus (HCV)
    • HIV - I & II
    • Syphilis Tp
    • Herpes Simplex Virus II (HSV) - IgG
    • Herpes Simplex Virus II (HSV) - IgM

STD Profile - Comprehensive Guide

  • Why is it done?
    • The STD Profile is a comprehensive screening panel designed to detect sexually transmitted infections (STIs) and blood-borne pathogens that pose significant public health risks
    • Provides simultaneous detection of multiple infections caused by bacteria, viruses, and parasites commonly transmitted through sexual contact
    • Primary indications include routine STI screening in sexually active individuals, pre-marital health assessment, evaluation of sexual abuse or assault, pregnancy screening, and monitoring of high-risk populations
    • Recommended for individuals presenting with symptoms of STI (genital discharge, ulcers, pelvic pain, dysuria), those with multiple sexual partners, and those in relationships where a partner has been diagnosed with an STI
    • HBsAg detects active Hepatitis B infection and infectivity status by identifying the surface antigen of Hepatitis B virus
    • Anti-Chlamydia trachomatis IgG antibody testing identifies past or persistent infection, while IgM antibody indicates recent or acute infection with this intracellular bacterium
    • Anti-HCV testing screens for Hepatitis C virus exposure and past or current infection through antibody detection
    • HIV I & II testing detects antibodies against both major types of human immunodeficiency virus, which causes AIDS
    • Syphilis Tp (Treponemal pallidum) testing detects antibodies against the causative organism of syphilis, a chronic systemic infection
    • HSV-II IgG and IgM testing distinguishes between past/chronic genital herpes infection (IgG) and acute/recent infection (IgM)
    • These tests work synergistically to provide comprehensive coverage of the most common and medically significant sexually transmitted pathogens in a single blood draw
  • Normal Range
    • HBsAg: Negative or <0.05 mIU/mL - Absence of Hepatitis B surface antigen indicates no current infection or immunity from vaccination
    • Anti-Chlamydia trachomatis IgG: Negative or <1.0 Index - Indicates no prior exposure or resolved infection; Positive (≥1.1 Index) suggests past or persistent infection
    • Anti-Chlamydia trachomatis IgM: Negative or <1.0 Index - Normal finding; Positive (≥1.1 Index) suggests recent or acute infection
    • Anti-HCV: Negative or <1.0 Index - No Hepatitis C infection or exposure; Positive (≥1.1 Index) indicates past or current HCV infection
    • HIV I & II: Negative - No detectable antibodies against HIV; normal finding in uninfected individuals
    • Syphilis Tp: Negative or <1.0 Index - No exposure to Treponema pallidum; Positive (≥1.1 Index) indicates syphilis infection, past or current
    • HSV-II IgG: Negative or <0.90 Index - No prior HSV-II exposure; Positive (≥0.91 Index) indicates past or chronic genital herpes infection
    • HSV-II IgM: Negative or <0.90 Index - Normal; Positive (≥0.91 Index) suggests acute or recent HSV-II infection
  • Interpretation
    • HBsAg Positive: Indicates active Hepatitis B infection with potential for transmission; patient is infectious and requires immediate medical evaluation, assessment of disease stage (acute vs chronic), liver function testing, and monitoring for progression
    • HBsAg Negative: Patient either has never been infected, has recovered from past infection with immunity, or was successfully vaccinated
    • Anti-Chlamydia IgG Positive with IgM Negative: Indicates past Chlamydia infection with possible latent or chronic infection; may indicate treated infection or carrier state
    • Anti-Chlamydia IgM Positive: Suggests acute or recent Chlamydia trachomatis infection requiring treatment with antibiotics; may present with urethritis, cervicitis, or pelvic inflammatory disease
    • Both Anti-Chlamydia IgG and IgM Positive: Indicates acute infection superimposed on chronic or recurrent infection; warrants confirmatory testing and antibiotic therapy
    • Anti-HCV Positive: Indicates HCV infection (current or past); requires confirmation with HCV RNA PCR testing to determine active viremia; positive results mandate hepatology referral and liver assessment
    • Anti-HCV Negative: Indicates no HCV infection or exposure; however, testing in window period (first 4-6 weeks of infection) may produce false negative result
    • HIV I & II Positive: Indicates HIV infection; results require immediate confirmation with Western blot or HIV RNA (viral load) testing; patient is infectious and requires urgent antiretroviral therapy initiation and monitoring
    • HIV I & II Negative: No detectable HIV infection; however, window period testing (first 18-45 days) may produce false negatives requiring repeat testing after adequate seroconversion interval
    • Syphilis Tp Positive: Indicates syphilis exposure at any stage (primary, secondary, latent, or tertiary); serological patterns with RPR/VDRL determine stage and guide treatment decisions
    • Syphilis Tp Negative: No evidence of syphilis infection; indicates no exposure or testing during window period before antibody development
    • HSV-II IgG Positive: Indicates prior or chronic genital herpes simplex virus type 2 infection; patient may shed virus intermittently and transmit to partners
    • HSV-II IgM Positive: Suggests acute or recent primary HSV-II infection; presents with vesicular genital lesions, systemic symptoms, and requires antiviral therapy; heightened contagiousness during primary infection
    • Both HSV-II IgG and IgM Positive: Indicates acute recurrence in chronically infected patient; warrants antiviral therapy and counseling regarding transmission risk
    • False positive results can occur due to cross-reactivity, previous vaccinations, or autoimmune conditions; confirmatory testing is recommended for all positive results
  • Associated Organs
    • HBsAg - Liver (Primary): Hepatitis B virus directly attacks hepatocytes causing acute or chronic hepatitis; complications include cirrhosis, hepatic failure, and hepatocellular carcinoma; liver fibrosis can develop over 15-20 years of chronic infection
    • HBsAg - Kidneys and Blood vessels (Secondary): Immune complex deposition causes glomerulonephritis and polyarteritis nodosa; chronic infection increases cardiovascular disease risk
    • Anti-Chlamydia Antibodies - Urogenital Tract (Primary): Chlamydia trachomatis infects urethra, cervix, endometrium, and fallopian tubes; causes urethritis, cervicitis, endometritis, and salpingitis
    • Anti-Chlamydia Antibodies - Reproductive System (Secondary): Infection causes pelvic inflammatory disease (PID), ectopic pregnancy, infertility, and chronic pelvic pain in women; causes epididymitis and prostatitis in men
    • Anti-Chlamydia Antibodies - Eyes (Tertiary): Can cause reactive arthritis (Reiter's syndrome) and ocular complications including conjunctivitis and iritis
    • Anti-HCV - Liver (Primary): Hepatitis C virus causes chronic hepatitis in approximately 80% of infected individuals; leads to cirrhosis, hepatic decompensation, and hepatocellular carcinoma
    • Anti-HCV - Lymphoid System and Autoimmune Targets (Secondary): HCV causes cryoglobulinemia, vasculitis, and immune complex deposition affecting kidneys and blood vessels
    • HIV I & II - Lymphoid System and Immune Organs (Primary): HIV targets CD4+ T cells, causing progressive immunosuppression and lymphocyte depletion; affects lymph nodes, spleen, and bone marrow
    • HIV I & II - Multi-organ system (Secondary): AIDS progression causes opportunistic infections in lungs (PCP), brain (toxoplasmosis), GI tract (CMV), and systemic complications including Kaposi sarcoma
    • Syphilis Tp - Urogenital Tract (Primary Stage): Treponema pallidum causes primary chancre at inoculation site with regional lymphadenopathy
    • Syphilis Tp - Skin and Mucous Membranes (Secondary Stage): Causes diffuse rash, maculopapular lesions, and condyloma lata; involves entire body surface
    • Syphilis Tp - Cardiovascular and CNS Systems (Tertiary Stage): Causes aortitis, aortic aneurysm, neurosyphilis (general paresis), tabes dorsalis, and optic atrophy
    • HSV-II - Urogenital Tract and Genital Skin (Primary): Herpes simplex virus type 2 causes vesicular lesions, painful ulcers, and regional lymphadenopathy in genital region
    • HSV-II - Nervous System (Secondary): Causes sacral radiculitis, meningitis, and HSV encephalitis in severe cases; establishes latency in dorsal root ganglion with risk of recurrent disease
    • HSV-II - Systemic Complications: Can cause neonatal herpes during childbirth with severe disseminated disease; increases risk of HIV acquisition and transmission
  • Follow-up Tests
    • HBsAg Positive Follow-up: Anti-HBc (hepatitis B core antibody), Anti-HBs (hepatitis B surface antibody), HBeAg and Anti-HBe (e-antigen markers), HBV DNA PCR (viral load), liver function tests (ALT, AST, bilirubin, albumin), prothrombin time, and abdominal ultrasound for cirrhosis assessment
    • Anti-Chlamydia IgM Positive Follow-up: Nucleic acid amplification test (NAAT) from urethra/cervix for confirmation, urinalysis, pelvic ultrasound if PID suspected, partner notification and testing, post-treatment test of cure at 3-4 weeks after therapy completion
    • Anti-Chlamydia IgG Positive Follow-up: NAAT testing to determine current infection status, screen for complications if symptomatic, consider tubal patency testing if history of infertility, repeat serologies in 3-6 months to differentiate acute from chronic infection
    • Anti-HCV Positive Follow-up: HCV RNA PCR (viral load) to confirm active infection, HCV genotyping to guide antiviral therapy selection, liver function panel, platelet count, assessment for cirrhosis (FibroTest, transient elastography), hepatology referral, baseline ultrasound and AFP screening for HCC
    • HIV Positive Follow-up: Confirmatory Western blot or HIV RNA PCR, CD4+ T-cell count (baseline and monitoring), HIV viral load quantification, drug resistance testing, baseline genotype, chemistries for renal/hepatic function, opportunistic infection screening (TB, toxoplasmosis, CMV), immunization status assessment
    • Syphilis Tp Positive Follow-up: Rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) titer to assess disease stage and treatment response, treponemal pallidum particle agglutination (TP-PA) for confirmation, CSF examination if tertiary syphilis or neurosyphilis suspected, partner notification and treatment
    • Syphilis Tp Positive Follow-up Monitoring: Serial RPR/VDRL titers at 3, 6, and 12 months post-treatment to document four-fold titer decline; repeat at 24 months if titer remains stable but unsolved, surveillance for treatment failure indicators
    • HSV-II IgM Positive Follow-up: Clinical examination for vesicular lesions and ulcers, HSV PCR from lesion swab if available, viral culture from genital lesions, type-specific HSV-II serology at 4-6 weeks to confirm IgG seroconversion, partner notification and testing
    • HSV-II IgG Positive Follow-up: Clinical assessment for current symptoms or recurrent episodes, HSV-II IgM titering to confirm past infection, counsel on transmission risk to partners and neonates, initiate suppressive antiviral therapy if recurrent disease or transmission risk mitigation needed
    • Recommended monitoring frequency: Initial follow-up at 4-6 weeks after positive diagnosis; then quarterly if on treatment, semi-annually for 2 years in stable disease, and annually for chronic/latent infections
    • Comprehensive screening of sexual partners: All positive STD results require partner notification and testing with this complete STD profile; contact tracing essential for epidemiological control
  • Fasting Required?
    • No fasting required - The STD Profile is performed on blood serum and does not require fasting as food intake does not affect antibody or antigen detection
    • No specific medication restrictions - Most medications do not interfere with STI serology testing; however, inform healthcare provider of all current medications
    • Timing of testing is critical - For accurate results, testing should occur after adequate window period for antibody development: minimum 18-45 days for HIV (fourth-generation tests), 1-4 weeks for most bacterial infections, 4-6 weeks for HSV-II and HCV
    • Recent vaccinations should be noted - Hepatitis B vaccine history may affect HBsAg interpretation; discuss with phlebotomist
    • No dietary restrictions required - Patient may eat and drink normally before testing; maintain regular daily habits
    • Sample collection procedure: Standard venipuncture with serum separator tube (SST); approximately 5-10 mL blood required; multiple tests can be performed from single draw
    • Sample stability considerations: Serum samples are stable for 3-5 days at room temperature or 1-2 weeks if refrigerated at 2-8°C; freeze at -20°C for long-term storage
    • Pre-test counseling recommended - Discuss test purpose, result confidentiality, implications of positive findings, need for partner notification, and psychological support resources
    • No contraindications to testing - STD screening can be performed on pregnant individuals, those with active symptoms, or during acute illness without modifications

How our test process works!

customers
customers